GlassScriptPhysician profile
Khurram Abbass
NPI 1154455178
$13,275.41
in general payments reported to CMS, 2019-2025
30 companies · $3,267 in 2025
The $3,267 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $110 · 2021: $498 · 2022: $892 · 2023: $2,254 · 2024: $5,596 · 2025: $3,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,690 · Consulting Fee: $2,160 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,690.35 |
| Consulting Fee | $2,160.00 |
| Education | $265.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,112.21 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $2,472.94 | 2021-2025 | Rinvoq, Humira |
| Amgen INC. | $1,691.62 | 2019-2025 | Evenity, Enbrel, Prolia |
| Ucb, INC. | $1,300.66 | 2019-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $734.65 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $561.83 | 2019-2025 | Benlysta |
| Radius Health, INC. | $525.19 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $386.22 | 2019-2025 | Orencia |
| Pfizer INC. | $346.06 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $317.54 | 2024-2025 | Lupkynis |
| Genentech USA, INC. | $287.07 | 2019-2025 | Actemra, Gazyva |
| Fresenius Kabi USA, LLC | $203.69 | 2023-2024 | Idacio, Tyenne |
| Sobi, INC | $154.30 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $124.26 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $116.91 | 2023 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $115.22 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $110.92 | 2019 | |
| Lilly USA, LLC | $106.39 | 2023-2025 | Taltz |
| Alexion Pharmaceuticals, INC. | $90.00 | 2024-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $70.88 | 2025 | Acthar |
| Kiniksa Pharmaceuticals International, Plc | $70.79 | 2024 | Arcalyst |
| Celltrion USA INC. | $70.33 | 2023-2025 | Yuflyma, Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.46 | 2023-2024 | Cyltezo |
| Horizon Therapeutics Plc | $53.69 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $52.50 | 2024-2025 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $48.36 | 2024 | Crysvita |
| Genzyme Corporation | $43.98 | 2019-2023 | |
| Myriad Genetic Laboratories, INC. | $22.67 | 2024 | Myrisk |
| Medexus Pharma, INC. | $13.16 | 2019 | |
| Celgene Corporation | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khurram Abbass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.